Skip to content
Subscriber Only
Opinion
Chris Hughes

For Bayer, a Roundup Deal Would Be Billions Well Spent

Shareholders want a legal settlement, even if it costs $8 billion.

A bottle of Bayer AG Roundup brand weedkiller.

A bottle of Bayer AG Roundup brand weedkiller.

Photographer: Daniel Acker/Bloomberg

Bayer AG shareholders are daring to imagine a future free of the litigation that has dogged the pharma group’s Roundup weedkiller. It’s an increasingly plausible scenario, and one investors are itching to price in.

Evidence is mounting that the German drugmaker is serious about settling the thousands of claims alleging Roundup is responsible for cancer. Bayer’s lawyers have suggested a deal worth between $6 billion and $8 billion, Bloomberg News reported on Friday. The talks are sufficiently advanced that lawyers are seeking a delay to upcoming court cases.